Pacer Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.2M | Sell |
39,986
-5,495
| -12% | -$453K | 0.01% | 754 |
|
|
2025
Q4 | $3.88M | Sell |
45,481
-2,836
| -6% | -$233K | 0.01% | 804 |
|
|
2025
Q3 | $3.76M | Sell |
48,317
-1,212
| -2% | -$94.7K | 0.01% | 797 |
|
|
2025
Q2 | $3.87M | Buy |
49,529
+19,445
| +65% | +$1.45M | 0.01% | 794 |
|
|
2025
Q1 | $2.18M | Sell |
30,084
-17,084
| -36% | -$1.22M | 0.01% | 921 |
|
|
2024
Q4 | $3.49M | Sell |
47,168
-1,778
| -4% | -$124K | 0.01% | 766 |
|
|
2024
Q3 | $3.23M | Buy |
48,946
+2,384
| +5% | +$173K | 0.01% | 781 |
|
|
2024
Q2 | $4.3M | Sell |
46,562
-872
| -2% | -$77.2K | 0.01% | 628 |
|
|
2024
Q1 | $4.53M | Buy |
47,434
+7,337
| +18% | +$616K | 0.01% | 599 |
|
|
2023
Q4 | $3.06M | Sell |
40,097
-37,499
| -48% | -$2.61M | 0.01% | 681 |
|
|
2023
Q3 | $5.38M | Buy |
77,596
+16,986
| +28% | +$1.37M | 0.02% | 454 |
|
|
2023
Q2 | $5.72M | Buy |
60,610
+6,005
| +11% | +$522K | 0.02% | 505 |
|
|
2023
Q1 | $4.52M | Buy |
54,605
+52,376
| +2,350% | +$4.12M | 0.02% | 564 |
|
|
2022
Q4 | $166K | Sell |
2,229
-5,196
| -70% | -$400K | ﹤0.01% | 2331 |
|
|
2022
Q3 | $614K | Buy |
7,425
+134
| +2% | +$12.9K | ﹤0.01% | 679 |
|
|
2022
Q2 | $693K | Sell |
7,291
-24,817
| -77% | -$2.57M | 0.01% | 617 |
|
|
2022
Q1 | $3.78M | Sell |
32,108
-7,146
| -18% | -$802K | 0.03% | 476 |
|
|
2021
Q4 | $5.08M | Buy |
39,254
+544
| +1% | +$63.5K | 0.05% | 404 |
|
|
2021
Q3 | $4.38M | Sell |
38,710
-442
| -1% | -$50.5K | 0.06% | 469 |
|
|
2021
Q2 | $4.05M | Buy |
39,152
+4,905
| +14% | +$462K | 0.06% | 418 |
|
|
2021
Q1 | $2.86M | Sell |
34,247
-4,670
| -12% | -$395K | 0.05% | 417 |
|
|
2020
Q4 | $3.55M | Sell |
38,917
-11,719
| -23% | -$972K | 0.07% | 285 |
|
|
2020
Q3 | $4.04M | Sell |
50,636
-9,124
| -15% | -$712K | 0.09% | 183 |
|
|
2020
Q2 | $4.13M | Buy |
+59,760
| New | +$4.25M | 0.08% | 185 |
|
|
2020
Q1 | – | Sell |
-71,565
| Closed | -$5.57M | – | 818 |
|
|
2019
Q4 | $5.57M | Buy |
71,565
+2,451
| +4% | +$191K | 0.25% | 62 |
|
|
2019
Q3 | $5.07M | Buy |
69,114
+6,387
| +10% | +$449K | 0.11% | 173 |
|
|
2019
Q2 | $3.86M | Buy |
62,727
+6,693
| +12% | +$405K | 0.09% | 218 |
|
|
2019
Q1 | $3.57M | Buy |
+56,034
| New | +$3.2M | 0.1% | 185 |
|
|
2018
Q4 | – | Sell |
-34,272
| Closed | -$1.99M | – | 712 |
|
|
2018
Q3 | $1.99M | Buy |
34,272
+4,434
| +15% | +$217K | 0.07% | 330 |
|
|
2018
Q2 | $1.45M | Buy |
29,838
+6,336
| +27% | +$296K | 0.07% | 431 |
|
|
2018
Q1 | $1.09M | Buy |
23,502
+2,661
| +13% | +$116K | 0.06% | 424 |
|
|
2017
Q4 | $783K | Buy |
20,841
+4,905
| +31% | +$180K | 0.05% | 522 |
|
|
2017
Q3 | $581K | Buy |
15,936
+1,497
| +10% | +$57.1K | 0.05% | 584 |
|
|
2017
Q2 | $569K | Buy |
14,439
+1,122
| +8% | +$41K | 0.06% | 528 |
|
|
2017
Q1 | $418K | Buy |
13,317
+1,584
| +14% | +$49.6K | 0.05% | 593 |
|
|
2016
Q4 | $366K | Sell |
11,733
-72
| -0.6% | -$2.33K | 0.05% | 565 |
|
|
2016
Q3 | $474K | Sell |
11,805
-72
| -0.6% | -$2.71K | 0.07% | 387 |
|
|
2016
Q2 | $395K | Buy |
11,877
+831
| +8% | +$28.4K | 0.06% | 441 |
|
|
2016
Q1 | $325K | Sell |
11,046
-12
| -0.1% | -$331 | 0.07% | 278 |
|
|
2015
Q4 | $291K | Buy |
+11,058
| New | +$287K | 0.07% | 296 |
|
Other funds holding EW
VCM
VPM
Pacer Advisors's EW Position: Q1 2026 in Review
Pacer Advisors reduced its Edwards Lifesciences (EW) stake by 12% in Q1 2026, selling an estimated $453K and leaving 39,986 shares worth $3.2M. The position accounts for 0.01% of the portfolio, ranked #754.
Pacer Advisors first reported a position in EW in Q4 2015 and has held it in 40 quarters since. The position peaked at $5.72M in Q2 2023. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Pacer Advisors held 39,986 shares of Edwards Lifesciences worth $3.2M as of Q1 2026.
- Pacer Advisors sold 5,495 Edwards Lifesciences shares in Q1 2026, an estimated $453K.
- Edwards Lifesciences made up 0.01% of Pacer Advisors's portfolio in Q1 2026, its #754 holding.
- Pacer Advisors first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 40 quarters since.
- Pacer Advisors's Edwards Lifesciences position peaked at $5.72M in Q2 2023.
- 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.